Morphologic and histopathologic markers have been the backbone for the classification and prognostic assessment of melanoma. Availability of an increasing number of molecular markers, however, provides the potential for refining diagnostic and prognostic categories in this disease.
Methods
We reviewed the recent data that are accumulating concerning gene expression and genetic profiling and related these to clinical aspects of the disease.
Results
Multiple biomarkers have now been described, and their biologic significance is being established. In addition, several candidate molecules involved in mela-noma pathogenesis have been identified.
Conclusions
The process of biomarker identification and validation is providing a rapidly changing molecular view of melanoma, a strategy that is necessary for developing truly stratified or even personalized prevention or management.
NiezabitowskiA., CzajeckiK., RyśJ.,. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohisto-chemical study.J Surg Oncol.1999; 70(3): 150–160.
3.
BergerA.J., DavisD.W., TellezC.. Automated quantitative analysis of activator protein-2alpha subcellular expression in mela-noma tissue microarrays correlates with survival prediction.Cancer Res.2005; 65(23): 11185–11192.
4.
AlonsoS.R., OrtizP., PollánM., Pérez-GómezB.. Progression in cutaneous malignant mela-noma is associated with distinct expression profiles: a tissue microarray-based study.Am J Pathol.2004; 164(1): 193–203.
5.
JankuF., NovotnyJ., JulisI.. KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients.Melanoma Res.2005; 15(4): 251–256.
6.
CruzJ., Reis-FilhoJ.S., SilvaP.. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas.Oncology.2003; 65(1): 72–82.
7.
KraehnG.M., UtikalJ., UdartM.. Extra c-myc oncogene copies in high risk cutaneous malignant mela-noma and mela-noma metastases.Br J Cancer.2001; 84(1): 72–79.
8.
MassoumiR., KuphalS., HellerbrandC.. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma.J Exp Med.2009; 206(1): 221–232. Epub 2009 Jan 5.
9.
UdartM., UtikalJ., KrähnG.M.. Chromosome 7 aneusomy: a marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases.Neoplasia.2001; 3(3): 245–254.
10.
JovanovicB., KröckelD., LindenD.. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma.J Invest Dermatol.2008; 128(11): 2696–2704. Epub 2008 May 29.
11.
ReschkeM., Mihic-ProbstD., van der HorstE.H.. HER3 is a determinant for poor prognosis in melanoma.Clin Cancer Res.2008; 14(16): 5188–5197.
12.
PolskyD., MelzerK., HazanC.. HDM2 protein overexpression and prognosis in primary malignant melanoma.J Natl Cancer Inst.2002; 94(23): 1803–1806.
13.
WangY., DaiD.L., MartinkaM.. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.Clin Cancer Res.2007; 13(14): 4111–4116.
14.
UgurelS., HoubenR., SchramaD.. Microphthalmia-associated transcription factor gene amplification in metastatic mela-noma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response.Clin Cancer Res.2007; 13(21): 6344–6350.
15.
Mihic-ProbstD., MnichC.D., OberholzerP.A.. p16 expression in primary malignant mela-noma is associated with prognosis and lymph node status.Int J Cancer.2006; 118(9): 2262–2268.
16.
DaiD.L., MartinkaM., LiG.. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.J Clin Oncol.2005; 23(7): 1473–1482.
17.
RoeschA., BeckerB., MeyerS.. Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma.Mod Pathol.2005; 18(4): 565–572.
18.
MikhailM., VelazquezE., ShapiroR.. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation.Clin Cancer Res.2005; 11(14): 5153–5157.
19.
FlørenesV.A., MaelandsmoG.M., FayeR.. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.J Pathol.2001; 195(5): 530–536.
20.
FlørenesV.A., FayeR.S., MaelandsmoG.M.. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma.Clin Cancer Res.2000; 6(9): 3614–3620.
21.
WinnepenninckxV., LazarV., MichielsS.. Gene expression profiling of primary cutaneous mela-noma and clinical outcome.J Natl Cancer Inst.2006; 98(7): 472–482.
22.
GimottyP.A., Van BelleP., ElderD.E.. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma.J Clin Oncol.2005; 23(31): 8048–8056.
23.
OstmeierH., FuchsB., OttoF.. Prognostic immunohistochemical markers of primary human melanomas.Br J Dermatol.2001; 145(2): 203–209.
24.
FujimotoA., TakeuchiH., TabackB.. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma.Cancer Res.2004; 64(6): 2245–2250.
25.
FeckerL.F., GeilenC.C., TchernevG.. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis.J Invest Dermatol.2006; 126(6): 1366–1371.
26.
TasF., DuranyildizD., ArgonA.. Serum bcl-2 and survivin levels in melanoma.Melanoma Res.2004; 14(6): 543–546.
27.
DadrasS.S., PaulT., BertonciniJ.. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous mela-noma metastasis and survival.Am J Pathol.2003; 162(6): 1951–1960.
28.
WuH., BaruseviciusA., BabbJ.. Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential.J Cutan Pathol.2005; 32(2): 125–130.
29.
BachmannI.M., StraumeO., PuntervollH.E.. Importance of Pcadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.Clin Cancer Res.2005; 11 (24 pt 1): 8606–8614.
30.
ThiesA., MollI., BergerJ.. CEACAM1 expression in cutaneous malignant mela-noma predicts the development of metastatic disease.J Clin Oncol.2002; 20(10): 2530–2536.
31.
NishizawaA., NakanishiY., YoshimuraK.. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.Cancer.2005; 103(8): 1693–1700.
32.
AndersenK., NeslandJ.M., HolmR.. Expression of S100A4 com-bined with reduced E-cadherin expression predicts patient outcome in malignant melanoma.Mod Pathol.2004; 17(8): 990–997.
33.
SaalbachA., WetzelA., HausteinU.F.. Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating mela-noma cell adhesion to activated endothelium.Oncogene.2005; 24(29): 4710–4720.
34.
RedondoP., LloretP., IdoateM.. Expression and serum levels of MMP-2 and MMP-9 during human mela-noma progression.Clin Exp Dermatol.2005; 30(5): 541–545.
35.
MassiD., FranchiA., BorgognoniL.. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas.Hum Pathol.1999; 30(3): 339–344.
36.
LuongoV., PirozziG., CaracòC.,. HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma.Tissue Antigens.2004; 64(1): 84–87.
37.
SwartG.W., LunterP.C., KilsdonkJ.W.. Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of mela-noma cell clustering and cell migration?Cancer Metastasis Rev.2005; 24(2): 223–236.
38.
ScalaS., OttaianoA., AsciertoP.A.. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.Clin Cancer Res.2005; 11(5): 1835–1841.
39.
DuncanL.M., DeedsJ., HunterJ.. Down-regulation of the novel gene melastatin correlates with potential for mela-noma metastasis.Cancer Res.1998; 58(7): 1515–1520.
40.
WeinlichG., EisendleK., HasslerE.. Metallothionein: overexpression as a highly significant prognostic factor in melanoma. A prospective study on 1270 patients.Br J Cancer.2006; 94: 835–841.
41.
RangelJ., NosratiM., TorabianS.Osteopontin as a molecular prognostic marker for melanoma.Cancer.2008; 112(1): 144–150.
42.
CarvalhoL., LipayM., BelfortF.. Telomerase activity in prognostic histopathologic features of melanoma.J Plast Reconstr Aesthet Surg.2006; 59(9): 961–968. Epub 2006 Apr 3.
43.
CurtinJ.A., FridlyandJ., KageshitaT.. Distinct sets of genetic alterations in melanoma.N Engl J Med.2005; 353(20): 2135–2147.
44.
CurtinJ.A., BusamK., PinkelD.. Somatic activation of KIT in distinct subtypes of melanoma.J Clin Oncol.2006; 24(26): 4340–4346. Epub 2006 Aug 14.
45.
VirosA., FridlyandJ., BauerJ.. Improving mela-noma classification by integrating genetic and morphologic features.PLoS Med.2008; 5(6): e120.
46.
UgurelS., SchadendorfD., PföhlerC.. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.Clin Cancer Res.2006; 12(18): 5454–5463.
47.
GuoH.B., Stoffel-WagnerB., BierwirthT.. Clinical significance of serum S100 in metastatic malignant melanoma.Eur J Cancer.1995; 31A(11): 1898–1902.
48.
SchultzE.S., DiepgenT.L., Von Den DrieschP.. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma.Br J Der-matol.1998; 138(3): 426–430.
49.
HauschildA., EngelG., BrennerW.. Predictive value of serum S100B for monitoring patients with metastatic mela-noma during chemotherapy and/or immunotherapy.Br J Dermatol.1999; 140(6): 1065–1071.
50.
KrähnG., KaskelP., SanderS.. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred mela-noma metastases compared with MIA, albumin and lactate-dehydrogenase.Anticancer Res.2001; 21 (2B): 1311–1316.
51.
GarbeC., LeiterU., EllwangerU.. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk mela-noma patients.Cancer.2003; 97(7): 1737–1745.
52.
BogdahnU., ApfelR., HahnM.. Autocrine tumor cell growthinhibiting activities from human malignant melanoma.Cancer Res.1989; 49(19): 5358–5363.
53.
BleschA., BosserhoffA.K., ApfelR.. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA.Cancer Res.1994; 54(21): 5695–5701.
54.
StahleckerJ., GaugerA., BosserhoffA.. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.Anticancer Res.2000; 20 (6D): 5041–5044.
55.
AgrupP., CarstamR., WittbjerA.. Tyrosinase activity in serum from patients with malignant melanoma.Acta Derm Venereol.1989; 69(2): 120–124.
56.
WimmerI., MeyerJ.C., SeifertB.. Prognostic value of serum 5-Scysteinyldopa for monitoring human metastatic mela-noma during immunochemotherapy.Cancer Res.1997; 57(22): 5073–5076.
57.
StoitchkovK., LetellierS., GarnierJ.P.. Evaluation of the serum L-dopa/L-tyrosine ratio as a mela-noma marker.Melanoma Res.2003; 13(6): 587–593.
58.
UgurelS., RapplG., TilgenW.. Increased serum concentration of angiogenic factors in malignant mela-noma patients correlates with tumor progression and survival.J Clin Oncol.2001; 19(2): 577–583.
59.
HiraiS., KageshitaT., KimuraT.. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of mela-noma progression.Melanoma Res.1997; 7(1): 58–62.
60.
VuoristoM.S., LaineS., HuhtalaH.. Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma.Eur J Cancer.2001; 37(13): 1629–1634.
61.
FranzkeA., Probst-KepperM., BuerJ.. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehy-drogenase as predictors of survival in cutaneous metastatic malignant melanoma.Br J Cancer.1998; 78(1): 40–45.
62.
NikkolaJ., VihinenP., VuoristoM.S.. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.Clin Cancer Res.2005; 11(14): 5158–5166.
63.
YoshinoY., KageshitaT., NakajimaM.. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma.J Dermatol.2008; 35(4): 206–214.
64.
MouawadR., BenhammoudaA., RixeO.. Endogenous inter-leukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden.Clin Cancer Res.1996; 2(8): 1405–1409.
65.
DummerW., BeckerJ.C., SchwaafA.. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma.Melanoma Res.1995; 5(1): 67–68.
66.
NemunaitisJ., FongT., ShabeP.. Comparison of serum inter-leukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma.Cancer Invest.2001; 19(3): 239–247.
67.
BoyanoM.D., Garcia-VázquezM.D., López-MichelenaT.. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.Br J Cancer.2000; 83(7): 847–852.
68.
RebmannV., UgurelS., TilgenW.. Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage mela-noma patients.Int J Cancer.2002; 100(5): 580–585.
69.
WesthoffU., FoxC., OttoF.J.. Soluble HLA class I antigens in plasma of patients with malignant melanoma.Anticancer Res.1998; 18 (5B): 3789–3792.
70.
SirottM.N., BajorinD.F., WongG.Y.. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis.Cancer.1993; 72(10): 3091–3098.
71.
DeichmannM., KahleB., MoserK.. Diagnosing mela-noma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase.Br J Cancer.2004; 91(4): 699–702.
72.
UgurelS., BellN., SuckerA.. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.Int J Cancer.2005; 117(5): 825–830.
73.
UgurelS., RapplG., TilgenW.. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in mela-noma patients.Clin Cancer Res.2001; 7(5): 1282–1286.
74.
SchmidtH., JohansenJ.S., SjoegrenP.. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.J Clin Oncol.2006; 24(5): 798–804. Epub 2006 Jan 3.
75.
SchmidtH., JohansenJ.S., GehlJ.. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.Cancer.2006; 106(5): 1130–1139.
76.
VergilisI.J., SzarekM., FerroneS.. Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma.J Invest Dermatol.2005; 125(3): 526–531.
77.
HahnS., UgurelS., HanschmannK.M.. Serological response to human endogenous retrovirus K in mela-noma patients correlates with survival probability.AIDS Res Hum Retroviruses.2008; 24(5): 717–723.
78.
PerssonL., HårdemarkH.G., GustafssonJ.. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system.Stroke.1987; 18(5): 911–918.
79.
DeichmannM., BennerA., BockM.. S100-Beta, melanomainhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.J Clin Oncol.1999; 17(6): 1891–1896.
80.
JuryC.S., McAllisterE.J., MacKieR.M.. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.Br J Dermatol.2000; 143(2): 269–274.
81.
AclandK., EvansA.V., AbrahaH.. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma.Br J Dermatol.2002; 146(5): 832–835.
82.
BalchC.M., BuzaidA.C., SoongS.J.. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.J Clin Oncol.2001; 19(16): 3635–3648.
83.
MianS., UgurelS., ParkinsonE.. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in mela-noma patients.J Clin Oncol.2005; 23: 5088–5093.
84.
FindeisenP., ZapatkaM., PeccerellaT.. Serum amyloid A as a prognostic marker in mela-noma identified by proteomic profiling.J Clin Oncol.2009 Mar 23. Epub ahead of print.
